Cell Therapy
Market Insight, CDMO Pricing and Competitor Benchmarking
Over 500 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Cell Therapy: Market Insight, CDMO Pricing and Competitor Benchmarking study.
Here are some facts about the report:
Research Started:
October 2024
Primary & Secondary Data Collection:
October 2024–November 2024
Collation & Analysis:
October 2024–November 2024
Development & Validation:
November 2024
Report Published:
November 2024
About This Report
This year we split the 2023 Cell and Gene Therapy report by modality, so that we can dive deeper into the production of cell therapies.
We have provided pricing for a typical mesenchymal stem cell therapy project in 2024. We now offer a unique perspective as we can comment on drivers of cell therapy manufacturing pricing.
We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.
We obtained input from subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.
We put the manufacturing market in context of ongoing geopolitical news.
Find Out Insights and Answers to These Questions
Innovators
Who are the major manufacturers in my target region?
Which CDMOs provide full end-to-end services, including development, manufacturing, formulation, and fill/finish?
How much do we need to budget for a typical cell therapy manufacturing program?
What companies are ahead of me in the clinical pipeline?
What viral vectors are used for different purposes and why?
What yields can we expect, and therefore at what scale do we prepare RFPs
Where are talent shortages most impacting CDMOs and what questions should I ask when evaluating a contractor?
What can we expect in the area of cell therapies?
What geopolitical news do I need to pay attention to?
Manufacturers
Who are my CDMO competitors in North America, Europe, and Asia?
What are the projected capacity expansions by my competitors, and where are they expanding?
How are competitors currently pricing their services?
Who are the key innovators in the space, and how many projects are in their portfolios?
What new cell therapy modalities does my firm need to consider developing a process for?
What is the scale required for our potential clients?
How are other firms dealing with a shortage of talent, and where might we find training programs?
What portion of the market is expected to come from cell therapies?
How might geopolitics affect my firm?
What’s Included in This Report
MSC Manufacturing Pricing
costs for key activities performed by CDMOs in this established industry
74 CDMO Profiles
including CDMOs with CAR-T and stem cell capacity and associated activities
Analysis of Clinical Trial Landscape
to understand the current and future cell therapies and manufacturing requirements
Market Growth Research
including projections for approved and late-stage cell therapy products
In-Depth Insight
from manufacturers and innovators on the IP, regulatory, technical, and financial landscape
Market Drivers
behind company expansions, layoffs, onshoring, and offshoring
Study Methodology
For the first edition of Nice Insight’s Cell Therapy: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking study we have focused only on the cell therapies from our previous report. We updated all of our trends sections with up-to-date primary, proprietary data and a survey of secondary data from the published literature and industry databases to create a comprehensive outsourced development and manufacturing of cell therapies. The quantitative research that we performed is supplemented by direct interviews conducted with multiple SMEs with diverse roles in the sector to obtain qualitative perspectives on the dynamics of the space.
The content included here reflects in total over 1,000 hours of dedicated research, interviews, analysis, and composition, both to develop the 2024 pricing study and survey of clinical trials published.
A team comprising six Ph.D.-level experts collaborated with a group of 25+ existing clients representing CDMOs within the cell therapy manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.
Our staff with over 100 years of industry experience worked for over two months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.
Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.